About
MitoCareX Bio is a drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with their proteins of interest, it uses its advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. The selected hit candidates are then progressed along the pre-clinical path.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of MitoCareX Bio's drug discovery efforts?
- MitoCareX Bio focuses on discovering and developing novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
- When was MitoCareX Bio founded?
- MitoCareX Bio was founded in February 2022.
- What is the current status of MitoCareX Bio?
- MitoCareX Bio was acquired by N2OFF in March 2025.
- What computational tool has MitoCareX Bio developed for drug discovery?
- MitoCareX Bio developed the MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for mitochondrial proteins, which is used for computer-aided drug design (CADD).
- What was a recent development in MitoCareX Bio's research scope?
- In January 2025, MitoCareX Bio expanded its research to include pancreatic cancer, following initial in-vitro positive results.
- Who is a known founder of MitoCareX Bio?
- Alon Silberman is a founder of MitoCareX Bio.
- How many employees does MitoCareX Bio have?
- MitoCareX Bio has 5 employees.